Cambridge Healthtech Institute’s 4th Annual

Implementing Risk-Based Monitoring – Part 1:  

Integrating Quality into Clinical Trials
February 13-14, 2018 | Hyatt Regency Orlando | Orlando, FL

Poor quality and risk management of clinical trials significantly impacts the success, timeliness and cost-effectiveness of clinical trials. Given the recent adoption of ICH E6 R2 changes, now is a critical time for the pharma industry to reflect on their processes and ensure quality across their clinical research activities, in particular, data management, and sponsor and investigator responsibilities. Cambridge Healthtech Institute’s 4th Annual Implementing Risk-Based Monitoring – Part 1: Integrating Quality into Clinical Trials conference provides guidance on how to holistically and proactively build quality standards into clinical trials with emphasis on the latest quality standards and guidelines, including the recent ICH-E6 R2 addendum changes, thereby ensuring higher quality clinical trials and laying the foundation for successful risk-based monitoring.

Monday, February 12

9:00 am - 7:30 pm Registration Open

5:00 - 6:15 pm Pre-Conference Plenary Keynote Panel

6:308:30 pm SCOPE’s Kick-Off Networking Happy Hour on the Garden Terrace Hosted by CHI, DrugDev, Exostar, & Praxis

8:30 Close of Day

Tuesday, February 13

7:15 am Registration Open and Morning Coffee

8:20 Opening Plenary Keynotes

9:45 Grand Opening Coffee Break in the Exhibit Hall

THE TRUE COST OF CLINICAL TRIAL QUALITY

10:45 Chairperson’s Remarks

Janis Little, Vice President, Global R&D Quality, Allergan

10:50 PANEL DISCUSSION: The Total Cost of Quality: Finding the Balance Between Investing in Quality and the Cost of Fixing Quality Problems

Moderator: Linda_SullivanLinda Sullivan, Co-Founder & President, Metrics Champion Consortium LLC


Panelists:

Armelde_PitreArmelde Pitre, MBA, Head, Quality Performance Analytics, Clinical Development Quality, Global Product Development, Pfizer, Inc.


Janis_LittleJanis Little, Vice President, Global R&D Quality, Allergan


Nicole_StansburyNicole Stansbury, Executive Director, Adaptive and Intelligent Monitoring, Clinical Development Services, PPD


Yusuf GhadialiYusuf Ghadiali, Senior Director, Performance Operational Capability, Global Clinical Operations, Biogen


Few organizations have a complete understanding of the financial impact of poor clinical trial quality. With better understanding of poor quality on an organization’s bottom line, it can improve buy-in for proactively investing in quality to avoid costly quality problems. In this panel, representatives from across pharma will come together to discuss the sources of poor clinical trial quality (ex. protocol amendments, low/non-enrolling sites, subjects dropping out, data quality issues, etc.), the challenges of estimating poor quality costs, current quality cost estimate techniques including the Cost of Poor Quality Estimator Tool developed by the MCC Study Quality Trailblazer Group, and how improved access to data about the cost of poor quality is impacting risk management and quality investment decisions.

CLINICAL QUALITY IN ACTION

11:40 Quality by Collaboration: Practical Applications

Jolie Weintraub, Executive Director, TA Head Oncology, MRL Quality Assurance, Merck

This presentation will discuss how quality is implemented within Merck, including the importance of collaborating with various quality functions at all levels of the organization. It will provide a holistic approach to supporting and achieving quality proactively throughout the clinical trial process. In addition, case studies will be shared on how this principle has been put into practice and steps to take to foster the collaborations.

PPD12:05 pm The Value of Centralized Monitoring on Monitoring Visits—Increasing Quality and Decreasing Costs

Nicole_StansburyNicole Stansbury, Executive Director, Adaptive and Intelligent Monitoring, Clinical Development Services, PPD

As regulatory authorities embrace change and the industry focuses on reducing costs, increasing data integrity and patient safety, the importance of centralized monitoring increases. PPD combines centralized monitoring with site health assessments to enhance site performance. Learn how our CRAs are moving from finding to fixing issues and becoming experts in process improvement to help sites become more engaged and efficient—ultimately reducing risk, increasing safety, ensuring quality and reducing the costs of drug development.

12:30 Session Break 

IQVIA12:40 Luncheon Presentation: The Role of Innovation and New Age Analytics in RBM Evolution

Rajneesh_PatilRajneesh Patil, Senior Director, Clinical Operations Process Design and Analytics, IQVIA

What problems are we looking to solve with innovation in RBM models. How do the new age analytics and advent of machine learning augment risk-based strategies. What results are we experiencing through implementation of statistical monitoring and analytics.

1:20 Coffee and Dessert Break in the Exhibit Hall

CLINICAL QUALITY IN ACTION (CONT.)

2:00 Chairperson’s Remarks

Linda Sullivan, Co-Founder & President, Metrics Champion Consortium LLC

2:05 TransCelerate’s Clinical QMS

Janis_LittleJanis Little, Vice President, Global R&D Quality, Allergan

The presentation will cover what a Clinical QMS is, and what the benefits are to sponsors in having a Clinical QMS defined and in place in alignment with ICH E6 (rev 2) requirements in Section 5. Audience will recognize and understand the flexibility of the TransCelerate Conceptual Framework for a Clinical QMS that will help sponsors design a customized CQMS for their specific needs. The presentation will dispel myths that exist on what a Clinical QMS “is” and what it is not, and it will cover what TransCelerate QMS publications and tools are currently available to industry. The presentation will also take a deep dive into a newly available tool for sponsors to assess a clinical quality management system (if they have implemented in alignment with the TransCelerate CQMS Conceptual Framework).

2:55 Envisioning a Quality Management System to Address the ICH E6 R2 Changes

Andy_LawtonAndy Lawton, Director and Consultant, Risk Based Approach Ltd.

The changes in ICH E6 R2 impact the fundamental basis of how quality should be addressed by a sponsor. This presentation will take a holistic look at the Regulatory background, and the tools that can be used to address the critical issues of Quality Tolerance Limits, Quality by Design, and Continuous Quality Improvement.

3:20 Risk-Based Monitoring Strategies for Improved Clinical Trial Performance

Henry_GalioHenry Galio, Senior Director, Vault CTMS, Veeva Systems

A strategic, risk-based approach to clinical trial management can aid sponsors and CROs in early detection and mitigation of risks that could affect the quality and safety of a study and its subjects. However, risk mitigation strategies have little value unless they are executed, monitored, and analyzed continuously throughout the trial’s lifecycle. This session explores how cloud-enabled solutions can be leveraged to gain real-time insights and actionable analytics to improve clinical trial safety and performance.

BREAKOUT DISCUSSION GROUPS

3:50 Find Your Table and Meet Your Moderator

4:00 Interactive Breakout Discussion Groups

Concurrent breakout discussion groups are interactive, guided discussions hosted by a facilitator or set of co-facilitators to discuss some of the key issues presented earlier in the day’s sessions. Delegates will join a table of interest and become an active part of the discussion at hand. To get the most out of this interactive session and format please come prepared to share examples from your work, vet some ideas with your peers, be a part of group interrogation and problem solving, and, most importantly, participate in active idea sharing.

5:00 Welcome Reception in the Exhibit Hall

6:30 Close of Day

Wednesday, February 14

7:15 am Registration Open

7:45 Breakfast Presentation: The Next Generation of Site Payments: Technology Do's and Don'ts

Stuart Thiede, President, Payments, DrugDev (An IQVIA Company)

Ineffective site payment processes can irreparably damage the site/sponsor relationship, resulting in the dreaded “one and done” mentality for many sites. However, leveraging a purpose-built technology solution can remove such concerns by ensuring reliable cycle times, efficient processing, real-time reporting, and transparency, all of which drive site satisfaction and simplify the lives of study teams. This session will highlight best practice technology and process models to ensure you achieve your site payment objectives.


8:15 Session Break

ICH E6 R2 & ITS IMPACT ON CLINICAL TRIAL QUALITY

8:25 Chairperson’s Remarks

Nithiya Ananthakrishnan, Senior Vice President, Data Science, OmniComm Systems

Covance8:30 CO-PRESENTATION: How an Ongoing Joint Risk-Based Monitoring Deployment Aligns with ICH E6 (R2)

Mike_WalegaMike Walega, Executive Director, Monitoring & Data Flow, Covance


Jude_BurgerJude Burger, MS, Manager, Eli Lilly

We will provide an overview of how an ongoing RBM deployment aligns with the new ICH GCP E6 (R2) guidelines. We will review the history of the deployment and the relevant aspects of E6 (R2). We will then focus on describing how this approach aligns with E6 (R2), where gaps exist, and how we plan to fill the gaps. Through examples and recommendations, we will provide attendees with insights to their own evolving RBM deployments.

9:20 How ICH E6 Updates Redefine How We Manage and Measure Quality

Linda_SullivanLinda Sullivan, Co-Founder & President, Metrics Champion Consortium LLC


9:45 Risk-Based Monitoring: Looking Beyond Risk

George H. JohnsonGeorge H. Johnson IV, SCPM, Product Manager & Senior Analyst, Clinical Analytics, PerkinElmer

There is mass concentration and growing need to adopt Risk-Based Monitoring given the obvious benefits to clinical trials. However, there is unspoken value beyond just KRIs and process changes. Join us as we discuss real-world cases of tangible benefits when looking beyond risk, including: RBM implementation best practices; what it means to look beyond the risk to implement QbD; quality improvements derived by rich RBM insights; driving CRO-Sponsor-Site relationships to the next level.

10:10 Coffee Break in the Exhibit Hall

ICH E6 R2 & ITS IMPACT ON CLINICAL TRIAL QUALITY (CONT.)

11:10 Chairperson’s Remarks

Nithiya Ananthakrishnan, Senior Vice President, Data Science, OmniComm Systems

11:15 PANEL DISCUSSION: ICH E6 and How the Industry Is Tackling Things Head On

Andy_LawtonModerator: Andy Lawton, Director and Consultant, Risk Based Approach Ltd.


Panelists:

Jonathan_RoweJonathan Rowe, Ph.D., Executive Director & Head, Quality Performance and Risk Management, Pfizer


Nithiya Ananthakrishnan, Senior Vice President, Data Science, OmniComm Systems


Nicole_StansburyNicole Stansbury, Executive Director, Adaptive and Intelligent Monitoring, Clinical Development Services, PPD

With the passage of ICH E6 (R2) addendum, the pharma industry is taking a closer look at how they approach clinical trial quality and oversight with their partners. This panel will cover how individual organizations are approaching ICH E6 R2 addendum changes, the struggles and challenges they faced or continue to face, and how they are working with other stakeholders (their CRO partners, stakeholders across different departments, etc.).

12:05 pm Session Break

12:10 Bridging Luncheon Presentation: Extracting Data from the EHR Dramatically Reduces the Need for Manual Monitoring - New Standards Make This Possible

Kim_RejndrupKim Rejndrup, Senior Vice President, Product Development, OmniComm

The typical workflow at an investigate site is for the patient data to be entered into the Electronic Health Record, then for the study coordinator to re-type that data into the EDC system. A big component of the subsequent Source Data Verification is simply checking that the retyping was done accurately. If data could instead flow automatically from the EHR system, with the coordinator just verifying the data in transit, then both the data entry and the subsequent SDV can be automated. New standards and technologies being introduced under the “SMART on FHIR” umbrella now make this possible. This presentation will describe the state of the art in this exciting new field.


12:50 Coffee and Dessert Break in the Exhibit Hall

1:30 Close of Conference

Melissa DolenGroup Discounts Are Available! Special rates are available for multiple attendees from the same organization. For more information on group discounts, contact Melissa Dolen at 781-972-5418 or mdolen@healthtech.com.


 

2018 SCOPE Conference at a Glance


For questions or suggestions about the meeting, contact:

Lee Yuan
Conference Director
Cambridge Healthtech Institute (CHI)
T: (+1) 781.972.5404
E: lyuan@healthtech.com

For partnering and sponsorship information, contact:

IlanaIlana Quigley
Senior Manager, Business Development
Cambridge Healthtech Institute (CHI)
T: (+1) 781.972.5457
E: iquigley@healthtech.com

For media and association partnerships, contact:

RichRich Handy
Senior Director, Marketing
Cambridge Healthtech Institute (CHI)
T: (+1) 781.972.5456
E: rhandy@healthtech.com

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Register Now

Download Brochure

CAG

Signature Sponsor

Premier Sponsors

>View All Sponsors


>Media Partners

>Attendee List

>Attendee Profile

In Memory of Gerald “Jerry” Matczak
Matczak Jerry

Gerald “Jerry” Matczak, lead consultant in clinical innovation at Eli Lilly & Co., was a rare breed in the pharmaceutical world, someone who not only embraced social media, but also listened to activist patients. He has been a part of the SCOPE conference since its inception and won the Patient Engagement Award on Wednesday, the day before his passing. Matczak died suddenly on Feb. 2 at age 54. We will all miss him.

– Cambridge Healthtech Institute (CHI)